CN111718890B - Method for transdifferentiation of fibroblasts into glandular epithelial cells, culture system and application thereof - Google Patents
Method for transdifferentiation of fibroblasts into glandular epithelial cells, culture system and application thereof Download PDFInfo
- Publication number
- CN111718890B CN111718890B CN201910208841.4A CN201910208841A CN111718890B CN 111718890 B CN111718890 B CN 111718890B CN 201910208841 A CN201910208841 A CN 201910208841A CN 111718890 B CN111718890 B CN 111718890B
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- uterine
- epithelial cells
- fibroblasts
- cige
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 27
- 210000001703 glandular epithelial cell Anatomy 0.000 title claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 22
- 208000000509 infertility Diseases 0.000 claims abstract description 10
- 230000036512 infertility Effects 0.000 claims abstract description 10
- 231100000535 infertility Toxicity 0.000 claims abstract description 10
- 210000004907 gland Anatomy 0.000 claims abstract description 8
- 239000003112 inhibitor Substances 0.000 claims description 47
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims description 32
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims description 32
- 229940122439 Hydroxylase inhibitor Drugs 0.000 claims description 28
- 230000006698 induction Effects 0.000 claims description 21
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 20
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 20
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 16
- 102000001267 GSK3 Human genes 0.000 claims description 11
- 108060006662 GSK3 Proteins 0.000 claims description 11
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 11
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims description 11
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 10
- 101000942966 Mus musculus Leukemia inhibitory factor Proteins 0.000 claims description 10
- XZZHOJONZJQARN-UHFFFAOYSA-N 4-oxo-1h-1,10-phenanthroline-3-carboxylic acid Chemical compound C1=CN=C2C(NC=C(C3=O)C(=O)O)=C3C=CC2=C1 XZZHOJONZJQARN-UHFFFAOYSA-N 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- HIJMSZGHKQPPJS-UHFFFAOYSA-N 3-(6-methylpyridin-2-yl)-n-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide Chemical compound CC1=CC=CC(C=2C(=CN(N=2)C(=S)NC=2C=CC=CC=2)C=2C3=CC=CC=C3N=CC=2)=N1 HIJMSZGHKQPPJS-UHFFFAOYSA-N 0.000 claims description 7
- FXHHASJVTYRJHH-UHFFFAOYSA-N 1-[6-chloro-5-(trifluoromethoxy)-1h-benzimidazol-2-yl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=NC2=CC(Cl)=C(OC(F)(F)F)C=C2N1 FXHHASJVTYRJHH-UHFFFAOYSA-N 0.000 claims description 6
- CDJNNOJINJAXPV-UHFFFAOYSA-N 5-[1-[[2-(4-cyclopropylpiperazin-1-yl)pyridin-4-yl]methyl]-5-methylpyrazol-3-yl]-3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole Chemical compound CC1=CC(C=2ON=C(N=2)C=2C=CC(OC(F)(F)F)=CC=2)=NN1CC(C=1)=CC=NC=1N(CC1)CCN1C1CC1 CDJNNOJINJAXPV-UHFFFAOYSA-N 0.000 claims description 6
- MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- WXLPERVDMILVIF-UHFFFAOYSA-N n-[bis(4-methoxyphenyl)methyl]-6-oxo-2-pyridazin-3-yl-1h-pyrimidine-5-carboxamide Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)NC(=O)C1=CN=C(C=2N=NC=CC=2)N=C1O WXLPERVDMILVIF-UHFFFAOYSA-N 0.000 claims description 6
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 claims description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000000921 morphogenic effect Effects 0.000 claims description 5
- 230000008672 reprogramming Effects 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 37
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract description 15
- 230000000762 glandular Effects 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 12
- 229940011871 estrogen Drugs 0.000 abstract description 8
- 239000000262 estrogen Substances 0.000 abstract description 8
- 230000004044 response Effects 0.000 abstract description 8
- 229940088597 hormone Drugs 0.000 abstract description 7
- 239000005556 hormone Substances 0.000 abstract description 7
- 239000000186 progesterone Substances 0.000 abstract description 7
- 229960003387 progesterone Drugs 0.000 abstract description 7
- 230000001939 inductive effect Effects 0.000 abstract description 6
- 230000002611 ovarian Effects 0.000 abstract description 4
- 208000016599 Uterine disease Diseases 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000002357 endometrial effect Effects 0.000 abstract description 2
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- 230000003827 upregulation Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 34
- 210000000981 epithelium Anatomy 0.000 description 13
- 102000038624 GSKs Human genes 0.000 description 12
- 108091007911 GSKs Proteins 0.000 description 12
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000000654 additive Substances 0.000 description 9
- 230000000996 additive effect Effects 0.000 description 9
- 210000004291 uterus Anatomy 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102000012804 EPCAM Human genes 0.000 description 4
- 101150084967 EPCAM gene Proteins 0.000 description 4
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 4
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 4
- 101150057140 TACSTD1 gene Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000032692 embryo implantation Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000003856 Hypoxia-inducible factor-proline dioxygenases Human genes 0.000 description 3
- 108090000223 Hypoxia-inducible factor-proline dioxygenases Proteins 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 229940077150 progesterone and estrogen Drugs 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 2
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 101150067309 bmp4 gene Proteins 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 101150090422 gsk-3 gene Proteins 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102100034134 Activin receptor type-1B Human genes 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 1
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102000007460 S100 Calcium-Binding Protein A4 Human genes 0.000 description 1
- 108010085149 S100 Calcium-Binding Protein A4 Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HHRZAEJMHSGZNP-UHFFFAOYSA-N mebanazine Chemical compound NNC(C)C1=CC=CC=C1 HHRZAEJMHSGZNP-UHFFFAOYSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000012049 whole transcriptome sequencing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/71—Oxidoreductases (EC 1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
The invention relates to a method for transdifferentiating fibroblasts into glandular epithelial cells, a culture system and application thereof. The invention obtains chemically induced glandular epithelial cells (ciGE) with uterine glandular epithelial characteristics and response to ovarian hormones, which can be applied to the aspects of endometrial replacement and the like in clinical treatment. Obtaining ciGE by inducing fibroblasts using only chemical molecules has several advantages including cell permeability, ease of handling, lack of immunogenicity and ease of standardization, which make it an attractive strategy for clinical applications in the treatment of uterine disorders such as Absolute Uterine Factor Infertility (AUFI). Furthermore, the present inventors have found that upregulation of functionally related genes, including estrogen and progesterone response genes in ciGE, indicates that the obtained ciGE is an amplifiable functional uterine gland epithelial cell.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a method for transdifferentiating fibroblasts into glandular epithelial cells and a culture system and application thereof.
Background
Worldwide, approximately 15% suffer from infertility disorders, where infertility due to uterine abnormalities-Absolute Uterine Factor Infertility (AUFI) accounts for 3% -5% of the total female population. Currently, the primary method of treating AUFI is uterine transplantation (UTx) (see also
M., et al, transplantation 102, 569-577 (2018)). However, limited organ availability and ethical issues limit the widespread use of this technology. The artificial uterus can be used as an embryo incubator, and brings hopes to women with damaged or diseased uterus. The artificial uterus needs complete structure and sufficient cell sources, and the current cell sources are insufficient, so that the clinical application of the biological artificial uterus is hindered. Mammalian uterine tissue includes the endometrium, which is composed primarily of the luminal epithelium, glandular epithelium, and stromal cells, and the myometrium. Among them, glandular epithelium is essential for embryo implantation, and it responds to ovarian hormones such as estrogen (E2) and progesterone (P4), synthesizes and secretes growth factors such as leukemia inhibitory factor (Lif) to promote embryo implantation and development. Numerous studies have shown that defects in glandular epithelium cause female infertility.
Mammalian uterine Glandular Epithelium (GE) is essential for blastocyst implantation, and its deficiency can lead to infertility (see Gu, T.P., et al. Nature 477,606-610 (7366)). GE responds to ovarian hormones, estrogens and progesterone and induces the expression of embryonic implanted Lif (see Carson, D.D., et al. Dev Biol223, 217-684 (2000), and Demir, R., et al. Placenta 23, 672-684 (2002)). Reprogramming fibroblasts directly by specific Transcription Factors (TF) or chemical molecules has been previously reported (see Cieslar-Pobuda, A., et al, Biochim Biophys Acta Mol Cell Res 1864, 1359-. However, few reports have been made on obtaining uterine cells by fibroblast reprogramming.
Disclosure of Invention
The invention firstly utilizes a chemical method to directly transdifferentiate fibroblasts into glandular epithelial cells. The invention develops a culture system for expanding the epithelial cells of the uterine gland in vitro for a long time, and can provide a cell source for a mouse model for treating infertility caused by uterine factors and provide a cell source for in vitro reconstruction of the uterus.
The present invention has been completed based on the following findings of the inventors: the present invention has been accomplished by utilizing a culture system containing small chemical molecules to directly reprogram fibroblasts into glandular epithelial cells.
The invention therefore relates to a method for transdifferentiating fibroblasts into glandular epithelial cells, characterized in that a proline hydroxylase inhibitor is used in the induction process.
The invention relates to a non-therapeutic method for transdifferentiation of fibroblasts into glandular epithelial cells, characterized in that a proline hydroxylase inhibitor is used during the induction process.
The invention also relates to a culture system for in vitro amplification of uterine glandular epithelial cells, wherein the culture system comprises a proline hydroxylase inhibitor.
In the above embodiments, the proline hydroxylase inhibitor is a HIF prolyl 4-hydroxylase inhibitor.
In the above embodiments, the proline hydroxylase inhibitor is a HIF α prolyl 4-hydroxylase inhibitor.
In the above embodiment, the proline hydroxylase inhibitor is one or more of 1,4-DPCA, BAY87-2243, MK-8617, and JNJ-42041935. Wherein the structural formulas of the 1,4-DPCA, the BAY87-2243, the MK-8617 and the JNJ-42041935 are shown as follows.
Herein, the "proline hydroxylase inhibitor" is a substance capable of inhibiting the activity of Proline Hydroxylase (PH), and has the same mechanism of action to promote the stabilization of hypoxia inducible factor by inhibiting proline hydroxylase. The above proline hydroxylase inhibitors are known as common proline hydroxylase inhibitors.
In the above embodiment, an ALK inhibitor is also added during the induction process or in the culture system.
In the above embodiments, the ALK inhibitor is an ALK5 inhibitor.
In the above embodiments, the ALK inhibitor is one or more of a83-01, RepSox, SB 431542. Wherein, the structural formulas of A83-01, RepSox and SB431542 are shown as follows.
Herein, the "ALK 5 inhibitor" is a substance capable of inhibiting Aurora-like kinase (ALK-like kinase5, ALK5, which is a transforming growth factor signal-beta (TGF-beta) receptor), has the same action mechanism, and further inhibits the transforming growth factor-beta signal pathway by inhibiting ALK 5. The ALK5 inhibitors described above are all known commonly used ALK5 inhibitors.
In the above embodiment, a GSK inhibitor is also added to the induction process or the culture system.
In the above embodiments, the GSK inhibitor is a GSK3 α/β inhibitor.
In the above embodiment, the GSK inhibitor is one or more of CHIR99021 and CHIR-98014. Wherein the structural formulas of CHIR99021 and CHIR-98014 are shown as follows.
Herein, the "GSK 3 α/β inhibitor" is a substance capable of inhibiting glycogen synthase (GSK 3 α/β), has the same action mechanism, and activates Wnt signaling pathway by inhibiting GSK3 α/β. The GSK inhibitors are known as common GSK3 alpha/beta inhibitors.
In the above embodiment, any one or more of fibroblast growth factor 2(FGF2), bone morphogenetic protein 4(BMP4), and mouse leukemia inhibitory factor (mLif) is further added to the induction process or the culture system.
The invention also relates to the non-therapeutic use of any one of the above inhibitors or a combination of any two or three of them in stimulating fibroblast transdifferentiation.
The invention also relates to the application of any one of the inhibitors or the combination of any two or three of the inhibitors in preparing a medicament for stimulating the transdifferentiation of fibroblasts.
In one embodiment, said stimulated fibroblasts transdifferentiate into fibroblasts that transdifferentiate into glandular epithelial cells.
The invention also relates to the use of the above method and/or culture system to provide a source of cells for a mouse model for the treatment of infertility caused by uterine factors, or for in vitro reconstruction of the uterus.
In the present invention, the term "non-therapeutic" refers to the methods and/or uses of the present invention excluding the methods of diagnosis and treatment of diseases specified in article 25 of the Chinese patent Law.
In the present invention, the inventors obtained chemically induced glandular epithelial cells (ciGE) with characteristics of uterine glandular epithelium and responsive to ovarian hormones, which means that they can be applied in clinical treatment for endometrial replacement.
Obtaining ciGE by inducing fibroblasts using only chemical molecules has many advantages including cell permeability, ease of handling, lack of immunogenicity and ease of standardization, which make it an attractive strategy for clinical application in the treatment of uterine diseases such as AUFI.
The present inventors have discovered that upregulation of functionally-associated genes, including estrogen and progesterone response genes in ciGE, indicates that the obtained ciGE is an amplifiable functional uterine glandular epithelial cell.
The invention also relates to application of any one or the combination of any two or three of a proline hydroxylase inhibitor, an ALK inhibitor and a GSK inhibitor in preparation of a medicine for treating uterine factor infertility.
The invention also relates to the application of any one or the combination of any two or three of the proline hydroxylase inhibitor, the ALK inhibitor and the GSK inhibitor in the preparation of a medicament for promoting uterine regeneration.
The invention provides a brand-new way for generating target cells by in-situ fibroblasts in damaged or aged uteruses through chemical molecule induction. It also provides an in vitro model for embryo implantation and study of uterine structure or function loss. Meanwhile, the invention provides a new way for treating the uterine factor infertility and uterine regeneration.
Drawings
Figure 1a protocol for reprogramming Mouse Embryo Fibroblasts (MEFs) to ciges using small molecule induction medium (FBLDAC).
Representative morphology of MEF-derived clones induced by FBLDAC induction medium. b left, control; b, right, day 12; c left, growth on matrigel; c right, grown on 10% FBS.
Figure 1d chemically induced epithelial cell expansion over 20 passages exhibiting a "38 + XX" karyotype.
Figure 1e chemically induced immunofluorescent staining of the epithelial cell characteristic protein KRT19, EPCAM, CDH1, scale 50 μm. The marker protein KI67 of the proliferating cells was immunofluorescent-stained with a 100 μm ruler.
FIG. 2.(Fsp1)-Cre/ROSA26 mTmG Fibroblasts are epithelial cells. (a) (Fsp1) -Cre/ROSA26 mTmG Schematic representation of fibroblasts. (b) Staining identifies epithelial cell fate of the starting fibroblasts. (c) GFP positive clones were generated after chemical induction. (d) Staining identifies epithelial cell fate after chemical induction.
FIG. 3. identification of chemically induced epithelial cells as glandular epithelial cell fates. (a) Heatmaps of RNA-Seq data and hierarchical clustering of genes. (b) Expression hotspot graph and Gene Ontology (GO) analysis of differentially expressed genes. (c-d) expression of genes specifically associated with uterine epithelial cells.
Figure 4. chemically induced uterine glandular epithelium has the ability to form glands. (a) Expression of adult stem/progenitor-related genes. (b) Self-assembled into a cavity structure, scale 75 μm.
Figure 5 chemically induced uterine glandular epithelium responds to stimulation by egg-derived hormones. (a-c) Progesterone response gene (5a), Estrogen response gene (5b) and uterine implantation related gene (5c) are all significantly upregulated. (d) MEF and chemistry induce uterine glandular epithelium in response to progesterone and estrogen stimulation.
Detailed Description
Specific embodiments of the present invention will be described in more detail below with reference to the accompanying drawings. While specific embodiments of the invention are shown in the drawings, it should be understood that the invention may be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
It should be noted that certain terms are used throughout the description and claims to refer to particular components. As one skilled in the art will appreciate, various names may be used to refer to a component. This specification and claims do not intend to distinguish between components that differ in name but not function. In the following description and in the claims, the terms "include" and "comprise" are used in an open-ended fashion, and thus should be interpreted to mean "include, but not limited to. The description which follows is a preferred embodiment of the invention, but is made for the purpose of illustrating the general principles of the invention and not for the purpose of limiting the scope of the invention. The scope of the present invention is defined by the appended claims.
As used herein, "substantially free" with respect to a particular component is used herein to mean that the particular component is not purposely formulated into the composition and/or is present only as a contaminant or in trace amounts. Thus, the total amount of a particular component resulting from any accidental contamination of the composition is less than 0.05%, preferably less than 0.01%. Most preferred are compositions wherein the amount of a particular component is not detectable by standard analytical methods.
As used in this specification, "a" or "an" may mean one or more. As used in the claims, the words "a" or "an" when used in conjunction with the word "comprising" may mean one or more than one.
The use of the term "or" in the claims is intended to mean "and/or" unless explicitly indicated to refer only to alternatives or that alternatives are mutually exclusive, although the disclosure supports definitions referring only to alternatives and "and/or". As used herein, "another" may mean at least a second or more.
Throughout this application, the term "about" is used to indicate that the value includes the inherent variation of error of the device, and the method is used to determine the value or variation that exists between subjects.
In this context, "differentiation" is the process by which less specialized cells become more specialized cell types. "dedifferentiation" is a cellular process in which partially or terminally differentiated cells revert to an earlier developmental stage, such as pluripotency or multipotency. "transdifferentiation" is the process of converting one differentiated cell type into another differentiated cell type. Typically, transdifferentiation occurs by programming without the cells going through an intermediate pluripotency stage-i.e., the cells are programmed directly from one differentiated cell type to another.
As used herein, the term "subject" or "subject in need thereof refers to a mammal, preferably a human, of any age, male or female, in need of cell or tissue transplantation. Typically, a subject is in need of a cell or tissue transplant (also referred to herein as a recipient) due to a disorder or pathological or undesirable condition, state or syndrome or physical, morphological or physiological abnormality that is amenable to treatment via cell or tissue transplant.
Some terms referred to herein are defined as follows:
FGF 2: fibroblast growth factor 2.
BMP 4: bone morphogenetic protein 4(bone morphogenetic protein 4, bmp 4).
mLif: mouse leukemia inhibitory factor.
High-glucose DMEM: a high-sugar DMEM medium (DMEM), a commercially available medium containing various glucose and amino acids, was developed on the basis of MEM medium.
N2B 27: a cell culture solution prepared by mixing a DMEM/F12 basal medium and a Neurobasal medium at a ratio of 1:1 and containing a N2 additive and a B27 additive, which is well-defined, is reported to be beneficial to the neural differentiation of mouse embryonic stem cells.
DMEM/F12: a commercial basal medium prepared by mixing DMEM medium and F12 medium at a ratio of 1:1 is suitable for clone density culture.
Neurobasal: is favorable for the commercial basic culture medium of the nerve cell culture.
N2 additive: a commercial serum-free cell culture additive.
B27 additive: a commercial serum-free cell culture additive.
1,4-DPCA, BAY87-2243, MK-8617, JNJ-42041935 proline hydroxylase inhibitors, wherein proline hydroxylase is an important enzyme for hypoxia inducible factor hydroxylation.
A83-01: a selective TGF-beta inhibitor can obviously inhibit the activities of ALK4, ALK5 and ALK 7.
Repssox: a potent and selective TGF beta R-1/ALK5 inhibitor.
SB 431542: a potent and selective ALK5 inhibitor.
CHIR 99021: a potent GSK-3 alpha/beta inhibitor.
CHIR-98014: a potent GSK-3 alpha/beta inhibitor.
The invention relates to a method for transdifferentiating fibroblasts into glandular epithelial cells, characterized in that a proline hydroxylase inhibitor is used in the induction process.
In the above embodiments, the proline hydroxylase inhibitor is a HIF prolyl 4-hydroxylase inhibitor.
In the above embodiments, the prolyl hydroxylase inhibitor is a HIF α prolyl 4-hydroxylase inhibitor.
In the above embodiment, the proline hydroxylase inhibitor is one or more of 1,4-DPCA, BAY87-2243, MK-8617, and JNJ-42041935.
In the above embodiment, an ALK inhibitor is also added during induction.
In the above embodiments, the ALK inhibitor is an ALK5/4/7 inhibitor.
In the above embodiments, the ALK inhibitor is one or more of a83-01, RepSox, SB 431542.
In the above embodiment, a GSK inhibitor is also added during induction.
In the above embodiments, the GSK inhibitor is a GSK3 α/β inhibitor.
In the above embodiment, the GSK inhibitor is one or more of CHIR99021 and CHIR-98014.
In the above embodiment, any one or more of fibroblast growth factor 2(FGF2), bone morphogenic protein 4(BMP4), mouse leukemia inhibitory factor (mLif) is also added during the induction process.
The invention also relates to the use of any one of the above inhibitors or a combination of any two or three of them for stimulating fibroblast transdifferentiation.
In one embodiment, said stimulated fibroblasts transdifferentiate into fibroblasts that transdifferentiate into glandular epithelial cells.
The invention also relates to a culture system for in vitro amplification of uterine glandular epithelial cells, wherein the culture system comprises a proline hydroxylase inhibitor.
In the above embodiments, the proline hydroxylase inhibitor is a HIF prolyl 4-hydroxylase inhibitor.
In the above embodiments, the proline hydroxylase inhibitor is a HIF α prolyl 4-hydroxylase inhibitor.
In the above embodiment, the proline hydroxylase inhibitor is one or more of 1,4-DPCA, BAY87-2243, MK-8617, and JNJ-42041935.
In the above embodiment, an ALK inhibitor is also added to the culture system.
In the above embodiments, the ALK inhibitor is an ALK5/4/7 inhibitor.
In the above embodiments, the ALK inhibitor is one or more of a83-01, RepSox, SB 431542.
In the above embodiment, a GSK inhibitor is further added to the culture system.
In the above embodiments, the GSK inhibitor is a GSK3 α/β inhibitor.
In the above embodiment, the GSK inhibitor is one or more of CHIR99021 and CHIR-98014.
In the above embodiment, any one or more of FGF2, BMP4, mLif is also added to the culture system.
The invention also relates to an induction culture solution for chemically reprogramming fibroblasts into glandular epithelial cells, which is characterized by comprising any one or more of 1,4-DPCA, A83-01, CHIR99021, FGF2, BMP4 and mLif.
The invention also relates to the use of the above method and/or culture system to provide a source of cells for a mouse model for the treatment of infertility caused by uterine factors, or for the ex vivo reconstruction of the uterus.
The following detailed description illustrates and describes embodiments of the present invention with reference to specific examples, but the following should not be construed as limiting the invention in any way.
Examples
The embodiments of the present invention will be described and illustrated in detail with reference to the following specific examples, but the following should not be construed as limiting the present invention in any way, and the materials and the like used in the examples are commercially available products unless otherwise specified.
Example one
Separating mouse day 13.5 embryo to prepare fetal fibroblast (MEFs), inoculating MEF cell in culture medium of 0.1% gelatin for one day, culturing with inducing culture solution containing small molecular compound for 12 days, changing the culture solution every 3 days, cloning to appear in culture time of 8-12 days, changing the culture medium into expanding culture solution EFLAC, culturing, and continuously expanding the cell in inducing culture solution for 1:4-1:6 passages. As shown in fig. 1a.
After 12 days of FBLDAC medium induction, MEF cells will be reprogrammed to epithelial-like clones, as shown in figure 1b, which can be stably passaged for more than 20 passages in matrigel or 10% FBS-covered dishes, as shown in figure 1c, and which have a stable karyotype of "38 + XX", as shown in figure 1d. These induced cells expressed specific marker genes for epithelial cells, such as KRT19, EPCAM and CDH1, and the proliferation protein KI67, as shown in figure 5.
The induction medium (FBLDAC) described above comprises: DMEM/F12(Gibco, 12400-024) and Neurabasal (Gibco, 21103-049) (1:1 mixture), N2 additive (Gibco, 17502-048, 200 ×), B27 additive (Gibco, 17504-044, 100 ×), fetal bovine serum (Gibco, 16000-044, 10%), GlutaMAX TM Supplement (Gibco, 35050079, 200 ×), serum replacement (Gibco, 10828028, 10%), beta-mercaptoethanol (Gibco, 21985, 55 μ M), bovine serum albumin (sigma, A7906-100G, 0.002%), fibroblast growth factor (FGF2, R7906, R)&D, 233-FB-001MG/CF, 20ng/mL), bone morphogenetic protein 4(BMP4, R)&D, 233-FB-001MG/CF, 10ng/mL), mouse leukemia inhibitory factor (mLif, Millipore, ESG1007, 1000)U/mL), penicillin streptomycin (Gibco, 15140-122, 100 x), and then chemical small molecule DAC: D, 1,4-DPCA (Enzo, BML-EI377-0050, 5. mu.M); a, A83-01(stemgent, 04-0014, 10. mu.M); c, CHIR99021(Stemgent, 04-0004, 12. mu.M).
The amplification culture solution comprises: [ DMEM/F12 and neurobasal (3:1), serum replacement (Gibco, 10828028, 2%), epidermal growth factor (R & D, 2028-EG-200, 100ng/mL), fibroblast growth factor (R & D, 233-FB-001MG/CF, 10ng/mL), mouse leukemia inhibitory factor (Millipore, ESG1007, 1000U/mL), A83-01(Stemgent, 04-0014, 5. mu.M), CHIR99021(Stemgent, 04-0004, 3. mu.M), heparin (sigma, H4784, 1. mu.g/mL), beta-mercaptoethanol (Gibco, 21985, 55. mu.M), bovine serum albumin (sigma, A7906-100G, 0.002)), non-essential amino acids (Gibco, 11140-plus 050, 100X N2 additive (Gibco, 17502, 200-048), 24X 048604, 864), and 27X 044).
Example two
Next, to evaluate the tumorigenicity of induced epithelial cells, we individually measured 5x 10 6 Each of the cigE and mouse Embryonic Stem Cells (ESC) was transplanted subcutaneously into hind limbs of 5-week-old Balb/c male nude mice, and the tumorigenic effect was monitored three weeks later. Our results show that 8 out of 10 mice transplanted with ESCs developed teratomas after 3 weeks, and that mice transplanted with cigE had no tumor formation after two months, as shown in Table 1.
TABLE 1 ratio of tumor formation
EXAMPLE III
To more strictly demonstrate that epithelial cells are indeed induced by MEF cells, we came from carrying fibroblast-specific protein 1(Fsp1) -Cre/ROSA26 mTmG In transgenic mice of (3) to isolate MEF for pursuitFibroblast cells are tracked. Fibroblasts permanently express membrane-targeted green fluorescent protein (mG) after Fsp1-Cre mediated excision of membrane-targeted tomato (mT) expression, as shown in FIG. 2 a. These tracking cells exclude contamination from epithelial cell fates and are induced according to the process shown in FIG. 1a. This result was more confirmed by the epithelial markers KRT19 and EPCAM staining, as shown in figure 2 b. The cells appeared green clones after FBLDAC induction as shown in figure 2 c. Induced epithelial cell fate was determined by staining for KRT19 and EPCAM staining, as shown in figure 2 d.
Example four
To further characterize these chemically induced epithelial cells, we performed whole transcriptome sequencing of ciGE, starting MEF and primary epithelial cells isolated from mouse uterus (priUterus), respectively. Clustering analysis showed that the gene expression pattern of ciGE is closely related to privters, but greatly different from MEF, as shown in fig. 3 a. By GO analysis, we found that the genes expressed in ciGE were associated with uterine development and estrogen response. Compared to MEF, ciGE is mainly enriched with GO terms related to epithelial cell fate and function, which was found to characterize ciGE with uterine glandular epithelium by comparison with reported data, as shown in fig. 3 b. The expression of the genes characteristic of the uterine gland epithelium (FOXA2 and SOX17) was verified by immunofluorescence staining and quantitative RT-PCR method, as shown in FIGS. 3c and 3 d.
And (3) immunofluorescence staining: cells were cultured on glass coverslips, then fixed with 4% PFA for 1 hour, followed by 3 washes with PBS. Cells were blocked with 0.1% Triton X-100 for 30 min and 2% BSA for 1 h at Room Temperature (RT). Cells were then incubated with primary antibody overnight at 4 ℃ and then with species-specific secondary antibody for 1 hour at room temperature. Cells were incubated with DAPI for 10 min at room temperature. Confocal microscopy (Leica TCS Sp8) images were taken. Antibody information used: anti-KRT19(Rabbit, Abcam, Ab52625, 1:500), anti-EPCAM (Rabbit, Abcam, Ab71916, 1:500), anti-CDH1(Rat, Sigma, U3254, 1:500), anti-KI67(Rabbit, Thermo Fisher Scientific, PA5-19462,1:200), anti-FO 2(Goat, Santa Cruz, Sc-9187, 1:200), anti-CD133(Rabbit, Abcam, Ab16518, 1:500), anti-SCA-1(Rat, Abcam, 51317, 1:500), anti-CDX2(Rabbit, Cell Signaling Technology, Ab 7s, 1: 200).
Quantitative PCR: total cellular RNA was extracted using TRIzol reagent (Invitrogen, 15596-018). A high capacity cDNA reverse transcription kit (ABI, 4368814) was used to reverse transcription of cDNA. Relative gene expression was analyzed based on the 2- Δ Δ Ct method, GAPDH as an internal control. The information of the primers used is shown in Table 2.
TABLE 2 primers used in quantitative PCR in examples IV, V and VI
EXAMPLE five
We further tested the high expression of somatic stem/progenitor markers in ciGE as shown in figure 4 a. The ciGE was partially digested with 0.25% trypsin, and the cell aggregates were gently pipetted out and plated onto matrigel-pre-coated petri dishes for 7-14 days. ciGE is able to form glandular-like structures with cavities that express epithelial proteins, which means that glandular production of ciGE can occur, as shown in figure 4 b.
EXAMPLE six
Further analysis showed that progesterone (E2) responsive gene (fig. 5a), estrogen (p4) responsive gene (fig. 5b) and uterine implantation related gene (fig. 5c) were all significantly up-regulated in the chemically induced uterine glandular epithelium. Under physiological conditions, the epithelium of the uterine gland can secrete factors such as Lif under the stimulation of ovogenous hormones such as progesterone and estrogen during pregnancy, so as to promote implantation and embryonic development. To further investigate whether these cells have the ability to respond to progesterone and estrogen stimulation. We incubated cigE or MEF with 8nM estrogen (Sigma, E8875) and 200ng/mL progesterone (Sigma, p8811) or DMSO (Sigma, D2650) for 3 days in amplification medium without mLif, N2 and B27 and collected the mRNA to identify gene expression. The results show that: compared to MEF, ciGE was significantly upregulated after hormone treatment in E2 and p4 response genes, as shown in fig. 5 d. These results indicate that small molecule induction media can reprogram fibroblasts into expandable functional uterine gland epithelial cells.
The foregoing merely illustrates the principles of the invention and it will thus be appreciated that the scope of the invention is not intended to be limited to the exemplary aspects described herein but is to include all equivalents currently known or developed in the future. In addition, it should be noted that several improvements and modifications can be made without departing from the technical principle of the present invention, and these improvements and modifications should also be construed as the scope of the present invention.
Sequence listing
<110> animal institute of Chinese academy of sciences
<120> method for transdifferentiation of fibroblasts into glandular epithelial cells, culture system and application thereof
<130> PC00464
<141> 2019-03-19
<160> 34
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213> Artificial sequence
<400> 1
aggtcggtgt gaacggattt g 21
<210> 2
<211> 23
<212> DNA
<213> Artificial sequence
<400> 2
tgtagaccat gtagttgagg tca 23
<210> 3
<211> 21
<212> DNA
<213> Artificial sequence
<400> 3
gtcttcagga caggggaaag a 21
<210> 4
<211> 20
<212> DNA
<213> Artificial sequence
<400> 4
cccctttaca gcagcaagat 20
<210> 5
<211> 19
<212> DNA
<213> Artificial sequence
<400> 5
<210> 6
<211> 22
<212> DNA
<213> Artificial sequence
<400> 6
acccactttt ctcatctcgt tc 22
<210> 7
<211> 20
<212> DNA
<213> Artificial sequence
<400> 7
ggcattcggg ctcctttctt 20
<210> 8
<211> 22
<212> DNA
<213> Artificial sequence
<400> 8
tggagtggta gtcgatgcta ag 22
<210> 9
<211> 21
<212> DNA
<213> Artificial sequence
<400> 9
ccctacgcca acatgaactc g 21
<210> 10
<211> 20
<212> DNA
<213> Artificial sequence
<400> 10
gttctgccgg tagaaaggga 20
<210> 11
<211> 21
<212> DNA
<213> Artificial sequence
<400> 11
attgtgccct tactgctgct g 21
<210> 12
<211> 22
<212> DNA
<213> Artificial sequence
<400> 12
gccagttgat tcttgatctg gt 22
<210> 13
<211> 19
<212> DNA
<213> Artificial sequence
<400> 13
<210> 14
<211> 19
<212> DNA
<213> Artificial sequence
<400> 14
<210> 15
<211> 19
<212> DNA
<213> Artificial sequence
<400> 15
<210> 16
<211> 19
<212> DNA
<213> Artificial sequence
<400> 16
ccaccacctc gcctttcac 19
<210> 17
<211> 21
<212> DNA
<213> Artificial sequence
<400> 17
gaggcagcag ttattgtgga t 21
<210> 18
<211> 21
<212> DNA
<213> Artificial sequence
<400> 18
cgttgacctt agtacccagg a 21
<210> 19
<211> 20
<212> DNA
<213> Artificial sequence
<400> 19
gggggttcag tacgcattgg 20
<210> 20
<211> 19
<212> DNA
<213> Artificial sequence
<400> 20
<210> 21
<211> 21
<212> DNA
<213> Artificial sequence
<400> 21
gccagctacc tggataaggt g 21
<210> 22
<211> 22
<212> DNA
<213> Artificial sequence
<400> 22
cagatgccag tcacgaatct tc 22
<210> 23
<211> 23
<212> DNA
<213> Artificial sequence
<400> 23
ccttgtggtt cttacgtttg ttg 23
<210> 24
<211> 22
<212> DNA
<213> Artificial sequence
<400> 24
cgttgacgac attctcaagc tg 22
<210> 25
<211> 19
<212> DNA
<213> Artificial sequence
<400> 25
<210> 26
<211> 22
<212> DNA
<213> Artificial sequence
<400> 26
ggttctgaga ttgctgggga tt 22
<210> 27
<211> 21
<212> DNA
<213> Artificial sequence
<400> 27
gcctgcaaat gcaaacaatg c 21
<210> 28
<211> 19
<212> DNA
<213> Artificial sequence
<400> 28
<210> 29
<211> 21
<212> DNA
<213> Artificial sequence
<400> 29
accaactgcg tacaagacga g 21
<210> 30
<211> 19
<212> DNA
<213> Artificial sequence
<400> 30
<210> 31
<211> 19
<212> DNA
<213> Artificial sequence
<400> 31
<210> 32
<211> 19
<212> DNA
<213> Artificial sequence
<400> 32
<210> 33
<211> 22
<212> DNA
<213> Artificial sequence
<400> 33
ctctgtcctt aaagcggctt ac 22
<210> 34
<211> 21
<212> DNA
<213> Artificial sequence
<400> 34
gttgcggagg ttcaagatgt t 21
Claims (7)
1. A non-therapeutic method for transdifferentiation of fibroblasts into uterine epithelial cells, comprising administering a HIF α prolyl 4-hydroxylase inhibitor, an ALK5 inhibitor, a GSK3 α/β inhibitor, fibroblast growth factor 2(FGF2), bone morphogenetic protein 4(BMP4) and mouse leukemia inhibitory factor (mLif) during induction.
2. A culture system for expanding uterine glandular epithelial cells in vitro, the culture system comprising a HIF α prolyl 4-hydroxylase inhibitor, an ALK5 inhibitor, a GSK3 α/β inhibitor, fibroblast growth factor 2(FGF2), bone morphogenic protein 4(BMP4), and mouse leukemia inhibitory factor (mLif).
3. The method of claim 1 or the culture system of claim 2, wherein the HIF α prolyl 4-hydroxylase inhibitor is selected from the group consisting of one or more of 1,4-DPCA, BAY87-2243, MK-8617, JNJ-42041935; the ALK5 inhibitor is selected from one or more of A83-01, RepSox and SB 431542; the GSK3 alpha/beta inhibitor is selected from one or more of CHIR99021 and CHIR-98014.
A non-therapeutic use of a combination of a HIF α prolyl 4-hydroxylase inhibitor, an ALK5 inhibitor, a GSK3 α/β inhibitor, fibroblast growth factor 2(FGF2), bone morphogenic protein 4(BMP4) and mouse leukemia inhibitory factor (mLif) in the stimulation of fibroblast transdifferentiation into uterine gland epithelial cells.
Use of a combination of a HIF α prolyl 4-hydroxylase inhibitor, an ALK5 inhibitor, a GSK3 α/β inhibitor, fibroblast growth factor 2(FGF2), bone morphogenic protein 4(BMP4) and mouse leukemia inhibitory factor (mLif) in the manufacture of a medicament for stimulating transdifferentiation of fibroblasts into uterine epithelial cells.
Use of a combination of a HIF α prolyl 4-hydroxylase inhibitor, an ALK5 inhibitor, a GSK3 α/β inhibitor, fibroblast growth factor 2(FGF2), bone morphogenic protein 4(BMP4) and mouse leukemia inhibitory factor (mLif) in the manufacture of a medicament for the treatment of uterine factor infertility and for the promotion of uterine regeneration.
7. An induction culture solution for chemically reprogramming fibroblast to be uterine gland epithelial cell, which is characterized by comprising 1,4-DPCA, A83-01, CHIR99021, FGF2, BMP4 and mLif.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910208841.4A CN111718890B (en) | 2019-03-19 | 2019-03-19 | Method for transdifferentiation of fibroblasts into glandular epithelial cells, culture system and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910208841.4A CN111718890B (en) | 2019-03-19 | 2019-03-19 | Method for transdifferentiation of fibroblasts into glandular epithelial cells, culture system and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111718890A CN111718890A (en) | 2020-09-29 |
| CN111718890B true CN111718890B (en) | 2022-08-09 |
Family
ID=72563225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910208841.4A Active CN111718890B (en) | 2019-03-19 | 2019-03-19 | Method for transdifferentiation of fibroblasts into glandular epithelial cells, culture system and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111718890B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110124101A (en) * | 2010-05-10 | 2011-11-16 | 고려대학교 산학협력단 | Generation composition for induced pluripotent stem cells with bmi1, mek inhibitor and gsk inhibitor treatment and method of manufacturing induced pluripotent stem cells using the same |
| CN103405404A (en) * | 2013-08-02 | 2013-11-27 | 浙江中医药大学 | Novel use of dimethyloxalglycine and mesenchymal stem cell separation method |
| CN104894060A (en) * | 2014-03-03 | 2015-09-09 | 中国科学院上海生命科学研究院 | Method for inducing transdifferentiation of somatic cells into neural stem cells and application thereof |
| WO2015192035A1 (en) * | 2014-06-13 | 2015-12-17 | Georgetown University | Compositions and methods for immortalization of epithelial cells |
| CN105829525A (en) * | 2013-10-03 | 2016-08-03 | 苏黎世联邦理工学院 | Reprogramming of pluripotent stem cells for improved control of their differentiation pathways |
-
2019
- 2019-03-19 CN CN201910208841.4A patent/CN111718890B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110124101A (en) * | 2010-05-10 | 2011-11-16 | 고려대학교 산학협력단 | Generation composition for induced pluripotent stem cells with bmi1, mek inhibitor and gsk inhibitor treatment and method of manufacturing induced pluripotent stem cells using the same |
| CN103405404A (en) * | 2013-08-02 | 2013-11-27 | 浙江中医药大学 | Novel use of dimethyloxalglycine and mesenchymal stem cell separation method |
| CN105829525A (en) * | 2013-10-03 | 2016-08-03 | 苏黎世联邦理工学院 | Reprogramming of pluripotent stem cells for improved control of their differentiation pathways |
| CN104894060A (en) * | 2014-03-03 | 2015-09-09 | 中国科学院上海生命科学研究院 | Method for inducing transdifferentiation of somatic cells into neural stem cells and application thereof |
| WO2015192035A1 (en) * | 2014-06-13 | 2015-12-17 | Georgetown University | Compositions and methods for immortalization of epithelial cells |
Non-Patent Citations (4)
| Title |
|---|
| "Hypoxia-inducible Factor 1 (HIF-1) Promotes Extracellular Matrix Remodeling under Hypoxic Conditions by Inducing P4HA1, P4HA2, and PLOD2 Expression in Fibroblasts";Daniele M. Gilkes 等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20130412;第288卷(第15期);第10819-10829页 * |
| "Reprogramming of fibroblasts to uterine glandular epithelium by a chemical cocktail induction";Xuewei Yuan 等;《Cell Discovery》;20190514;第5卷;第1-4页 * |
| "低氧诱导因子脯氨酸羟化域酶抑制剂研究进展";王明逍 等;《国际药学研究杂志》;20160430;第43卷(第2期);第249-259页 * |
| "化学诱导成纤维细胞为子宫腺上皮及其功能研究";袁雪薇;《中国学位论文全文数据库》;20191024;第1-74页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111718890A (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210338736A1 (en) | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same | |
| Tucker et al. | Use of a synthetic xeno-free culture substrate for induced pluripotent stem cell induction and retinal differentiation | |
| Barber et al. | Derivation of enteric neuron lineages from human pluripotent stem cells | |
| JP2022088599A (en) | Culture media, cell cultures, and methods of culturing pluripotent stem cells in undifferentiated state | |
| EP2443230B1 (en) | 3D CULTURING SYSTEMS FOR GROWTH AND DIFFERENTIATION OF HUMAN PLURIPOTENT STEM (hPS) CELLS | |
| JP6124347B2 (en) | Induction method and production method of hepatic progenitor cells with TGF-β signaling inhibitor and / or Y-27632, and production method of hepatocytes from the hepatic progenitor cells | |
| EP3483262B1 (en) | Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application | |
| KR20210040107A (en) | Hepato-biliary-pancreatic tissue and method of manufacturing the same | |
| EP2900069A1 (en) | Differentiation of human ips cells to human alveolar type ii via definitive endoderm | |
| CN110713973A (en) | Culture medium combination and method for inducing pluripotent stem cells to differentiate into mesenchymal stem cells | |
| JP2020506679A (en) | Maintenance and expansion of pancreatic progenitor cells | |
| CN103555661A (en) | Culture method free of multipotential stem cell without serum and feeder layer | |
| Illing et al. | Definitive endoderm formation from plucked human hair‐derived induced pluripotent stem cells and SK channel regulation | |
| Yuan et al. | A six-inhibitor culture medium for improving naïve-type pluripotency of porcine pluripotent stem cells | |
| US20110142935A1 (en) | Cardiac differentiation of human pluripotent stem cells under defined conditions using matrix overlay methods | |
| CA2908225A1 (en) | Method for culturing hepatoblast-like cells and culture product thereof | |
| KR101559481B1 (en) | Method for inducing differentiation of human pluripotent stem cells into nephron progenitor cells | |
| Pennarossa et al. | Combination of epigenetic erasing and mechanical cues to generate human epiBlastoids from adult dermal fibroblasts | |
| CN111718890B (en) | Method for transdifferentiation of fibroblasts into glandular epithelial cells, culture system and application thereof | |
| Gong et al. | Bi-potential hPSC-derived Müllerian duct-like cells for full-thickness and functional endometrium regeneration | |
| Talbot et al. | Establishment and characterization of feeder cell-dependent bovine fetal liver cell lines | |
| JP7148134B2 (en) | Stepwise induction method from hepatoblasts to bile duct epithelial progenitor cells | |
| CN117467599B (en) | Chemical inducer for reprogramming gonadal somatic cells of chickens into pluripotent stem cells of chickens and reprogramming method | |
| JP2008206510A (en) | Method for obtaining intestinal stem/precursor cell | |
| Pennarossa et al. | Generation of Artificial Blastoids Combining miR-200-Mediated Reprogramming and Mechanical Cues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |